Highest-materiality recent filing
Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand
Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.
Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M
Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.
Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue
Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).
Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M
GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.
Puma Biotechnology amends bylaws to align with Delaware law updates
Board adopted Fifth Amended and Restated Bylaws on June 19, 2025.
Eight directors elected; Troy E. Wilson received 24.3M for, 10.7M withheld, the largest withhold among nominees.
Puma Biotechnology terminates CCO Jeff J. Ludwig; no replacement named
Terminated Jeff J. Ludwig as Chief Commercial Officer and employee on May 8, 2025.
Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M
GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.
Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M
Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).
Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance
Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.
Puma reports judge invalidated Tagrisso patents; Wyeth appeals Sept 12
Jury awarded $107.5M for past infringement of '314 and '162 patents through Dec 2023.
Court invalidates Puma's patents in Tagrisso suit, overturns $107.5M jury award
Jury found Tagrisso infringed Puma's patents, awarded $107.5M in damages.
Puma Biotechnology wins patent suit vs AstraZeneca; $107.5M jury award upheld in bench trial
Jury found Tagrisso infringes Wyeth's patents; damages of $107.5M for past infringement through Dec 31, 2023.
Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M
Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.
Puma Biotechnology shareholders approve 3M share increase for equity plan, elect directors
Shareholders approved amendment to increase shares under 2011 plan by 3M to 17,529,412; ISO grants extended to March 2034.
Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca
Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.
Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%
Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.
Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13
Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.
Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M
Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.
Puma Biotechnology presents at B. Riley Oncology Conference; no material new information disclosed.
Presentation at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024.
On May 8, 2025, Puma Biotechnology, Inc. (the “Company”) terminated Jeff J. Ludwig as an employee and as its Chief Commercial Officer.
Max materiality 0.85 · Median 0.70 · Most common event earnings